RxDoctor Payments Data

Navin Kapur, MD

Cardiovascular Disease · Baltimore, MDNPI 1902959554

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $944,152 of the $1,511,271 with a category attached, or 62.5%. Abiomed accounts for 94.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $528,265 and has fallen 90.5% since, to $50,376 in 2025. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,511,271in general payments, 2019–2025

Across 501 payments — averaging $3016.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$1.4M
  • Livanova USA, Inc.$24K
  • My01 Inc.$21K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
  • Abbott$7K
  • Edwards Lifesciences$6K
  • plus $17K from 21 others
$402,957in research payments, 2019–2025

Across 43 payments — averaging $9371.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$150K
  • Abiomed$147K
  • Abbott$105K
  • ZOLL Circulation Inc$220

What the payments were for

  • Consulting fees$944,15262%
  • Speaking & faculty fees$433,45829%
  • Travel & lodging$122,1468%
  • Food & beverage$11,5161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,511,271 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$52,453
Medicare patients
303
Services billed
446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →